Successful systemic high‐dose ribavirin treatment of respiratory syncytial virus‐induced infections occurring pre‐engraftment in allogeneic hematopoietic stem cell transplant recipients

Respiratory syncytial virus (RSV) is a frequent cause of respiratory tract infectious disease (RTID) in allogeneic hematopoietic stem cell transplant (HSCT) recipients associated with a high mortality once infection has progressed from upper RTID (URTID) to lower RTID (URTID). Aerosolized ribavirin (RBV) is considered a cornerstone of treatment, but is expensive and has toxic side effects on patients and staff. In this study, RSV infection was detected by polymerase chain reaction (PCR) from routinely collected throat swabs in HSCT patients. Infected individuals were treated according to an institutional protocol using intravenous (IV) RBV for patients with LRTID and oral ribavirin for URTID.

[1]  R. Chemaly,et al.  Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. , 2011, Blood.

[2]  P. Ljungman,et al.  Respiratory Syncytial Virus Infection in Recipients of Allogeneic Stem-Cell Transplantation: A Retrospective Study of the Incidence, Clinical Features, and Outcome , 2009, Transplantation.

[3]  J. Schiffer,et al.  Timing and severity of community acquired respiratory virus infections after myeloablative versus non-myeloablative hematopoietic stem cell transplantation , 2009, Haematologica.

[4]  A. Gratwohl,et al.  Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  M. Boeckh,et al.  Respiratory virus infection among hematopoietic cell transplant recipients: evidence for asymptomatic parainfluenza virus infection. , 2007, Blood.

[6]  M. Boeckh,et al.  Randomized controlled multicenter trial of aerosolized ribavirin for respiratory syncytial virus upper respiratory tract infection in hematopoietic cell transplant recipients. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  M. Keating,et al.  Respiratory Viral Infections in Adults With Hematologic Malignancies and Human Stem Cell Transplantation Recipients: A Retrospective Study at a Major Cancer Center , 2006, Medicine.

[8]  A. Dudek,et al.  Hematopoietic stem cell transplant–related airflow obstruction , 2006, Current opinion in oncology.

[9]  J. Sierra,et al.  Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  L. Gürtler,et al.  Real-time PCR to improve the diagnosis of respiratory syncytial virus infection. , 2003, Journal of medical microbiology.

[11]  M. Siqueira,et al.  RESPIRATORY TRACT VIRAL INFECTIONS IN BONE MARROW TRANSPLANT PATIENTS , 2003, Transplantation.

[12]  C. Pannuti,et al.  Low mortality rates related to respiratory virus infections after bone marrow transplantation , 2003, Bone Marrow Transplantation.

[13]  C. Fegan,et al.  Respiratory virus infections in transplant recipients after reduced‐intensity conditioning with Campath‐1H: high incidence but low mortality , 2002, British journal of haematology.

[14]  M. Boeckh,et al.  Community-acquired respiratory syncytial virus and parainfluenza virus infections after hematopoietic stem cell transplantation: the Fred Hutchinson Cancer Research Center experience. , 2001, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  C. Fegan,et al.  Pre-emptive oral ribavirin therapy of paramyxovirus infections after haematopoietic stem cell transplantation: a pilot study , 2001, Bone Marrow Transplantation.

[16]  N. Russell,et al.  Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation , 2001, Bone Marrow Transplantation.

[17]  S. Crawford,et al.  Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. , 2001, The Journal of infectious diseases.

[18]  J. Moppett,et al.  The outcome of 26 patients with respiratory syncytial virus infection following allogeneic stem cell transplantation , 1999, Bone Marrow Transplantation.

[19]  P. Ljungman,et al.  Ribavirin therapy in bone marrow transplant recipients with viral respiratory tract infections , 1997, Bone Marrow Transplantation.

[20]  S. Crawford,et al.  Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation , 1996, Antimicrobial agents and chemotherapy.

[21]  R. Couch,et al.  Community respiratory virus infections among hospitalized adult bone marrow transplant recipients. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  B. Osborne,et al.  An outbreak of respiratory syncytial virus in a bone marrow transplant center. , 1992, The Journal of infectious diseases.

[23]  J. Connor,et al.  Environmental exposure of primary care personnel to ribavirin aerosol when supervising treatment of infants with respiratory syncytial virus infections , 1987, Antimicrobial Agents and Chemotherapy.

[24]  C. Hall,et al.  Ribavirin Treatment of Respiratory Syncytial Viral Infection in Infants With Underlying Cardiopulmonary Disease , 1985 .

[25]  C. Hall.  Ribavirin: beginning the blitz on respiratory viruses? , 1985, Pediatric infectious disease.

[26]  E. Walsh,et al.  Aerosolized ribavirin treatment of infants with respiratory syncytial viral infection. A randomized double-blind study. , 1983, The New England journal of medicine.

[27]  M. Boeckh,et al.  Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenzavirus, Metapneumovirus, Rhinovirus, and Coronavirus , 2012 .

[28]  H. Buxbaum-Conradi,et al.  Intravenous ribavirin for eradication of respiratory syncytial virus (RSV) and adenovirus isolates from the respiratory and/or gastrointestinal tract in recipients of allogeneic hematopoietic stem cell transplants. , 2004, The hematology journal : the official journal of the European Haematology Association.

[29]  J. Englund,et al.  Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin , 2000, Bone Marrow Transplantation.